Company profile: Allenex
1.1 - Company Overview
Company description
- Provider of products for blood stem cell and organ transplantation, including genomic HLA typing kits used prior to hematopoietic stem cell/bone marrow and organ transplants to match donors; develops, manufactures, markets, and sells worldwide.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allenex
Galapagos
HQ: Belgium
Website
- Description: Provider of small molecule medicines and investigational therapies in immunology and oncology. Develops CAR-T cell therapies via a decentralized manufacturing network and advances GLPG5101 (Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma). Conducts clinical trials to evaluate treatments and seek regulatory approval; Jyseleca (filgotinib) transferred to Alfasigma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galapagos company profile →
Immunic Therapeutics
HQ: United States
Website
- Description: Provider of selective oral immunology therapies, developing: Vidofludimus Calcium (IMU-838), an investigational oral drug for multiple sclerosis and other chronic inflammatory and autoimmune diseases with neuroprotective, anti-inflammatory and anti-viral effects; IMU-856, a Sirtuin 6–targeting small molecule to restore intestinal barrier and regenerate bowel epithelium for gastrointestinal diseases; and IMU-381, a next-generation GI candidate in preclinical testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunic Therapeutics company profile →
Sucampo Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialized biopharmaceuticals addressing unmet medical needs, with marketed products AMITIZA for chronic constipation and IBS-C in adults and RESCULA in Japan for lowering intraocular pressure in glaucoma or ocular hypertension, and a late-stage pipeline including VTS-270 for Niemann-Pick Disease Type C and CPP-1X/sulindac for Familial Adenomatous Polyposis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sucampo Pharmaceuticals company profile →
Q32 Bio
HQ: United States
Website
- Description: Provider of therapies for severe autoimmune and inflammatory diseases, including bempikibart (ADX-914), a fully human anti–IL-7 receptor alpha antagonist monoclonal antibody that blocks IL-7 and TSLP signaling to re-regulate adaptive immune function, and ADX-097, a humanized anti-C3d monoclonal antibody fusion protein aimed at restoring complement regulation via a tissue-targeted mechanism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q32 Bio company profile →
One Lambda
HQ: United States
Website
- Description: Provider of histocompatibility (HLA) typing tests using serological and molecular technologies, and manufacturer of antibody detection products, laboratory instrumentation, and computer software used to simplify and automate testing procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full One Lambda company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allenex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allenex
2.2 - Growth funds investing in similar companies to Allenex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allenex
4.2 - Public trading comparable groups for Allenex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →